Report associated factors that influence perfusion and risk, such as: recent vomiting, poor intake, dehydration, lightheadedness or fainting, blood pressure readings (especially if low), new or intensified antihypertensive therapy, and sleep apnea symptoms or CPAP nonadherence
Phase 3 trials evaluating oral semaglutide in early-stage symptomatic Alzheimers disease did not meet their primary endpoints, tempering the earlier hypothesis that GLP-1s might offer direct neuroprotective benefits
Existing safety summaries are confined to regulatory labels, narrative reviews, and individual pharmacovigilance reports, whereas gastrointestinal adverse effects dominate the published safety discourse
Adv Exp Med Biol 504:235248
From the friendly approach to the smooth booking experience, everything about this clinic is top-notch